nature medicine semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial Long-term kidney outcomes of semaglutide

A double-blind crossover clinical trial illustrated that GLP-1RA did not affect the hypothalamicpituitaryadrenal axis following long-term use in normal healthy volunteers (Winzeler et al

Additionally, oxidative stress, lipid peroxidation, and iron homeostasis imbalance exacerbate the aggregation of Htt with other proteins, leading to increased glutamate excitotoxicity, disrupted mitochondrial function, altered autophagy mechanisms, impaired axonal transport, and ultimately neuronal degeneration, thereby causing the motor, cognitive, and behavioral symptoms of HD (Reichert et al., 2020)

Semaglutide has demonstrated some efficacy in treating alcohol addiction

In This Article Both Trulicity and Ozempic are GLP-1 receptor agonists Both Trulicity (dulaglutide) and Ozempic (semaglutide) are GLP-1 receptor agonists that work the same way